Peral B, Gamble V, Strong C, Ong A C, Sloane-Stanley J, Zerres K, Winearls C G, Harris P C
MRC Molecular Haematology Unit, John Radcliffe Hospital, Oxford, Headington, United Kingdom.
Am J Hum Genet. 1997 Jun;60(6):1399-410. doi: 10.1086/515467.
Mutation screening of the major autosomal dominant polycystic kidney disease gene (PKD1) has been complicated by the large transcript size (> 14 kb) and by reiteration of the genomic area encoding 75% of the protein on the same chromosome (the HG loci). The sequence similarity between the PKD1 and HG regions has precluded specific analysis of the duplicated region of PKD1, and consequently all previously described mutations map to the unique 3' region of PKD1. We have now developed a novel anchored reverse-transcription-PCR (RT-PCR) approach to specifically amplify duplicated regions of PKD1, employing one primer situated within the single-copy region and one within the reiterated area. This strategy has been incorporated in a mutation screen of 100 patients for more than half of the PKD1 exons (exons 22-46; 37% of the coding region), including 11 (exons 22-32) within the duplicated gene region, by use of the protein-truncation test (PTT). Sixty of these patients also were screened for missense changes, by use of the nonisotopic RNase cleavage assay (NIRCA), in exons 23-36. Eleven mutations have been identified, six within the duplicated region, and these consist of three stop mutations, three frameshifting deletions of a single nucleotide, two splicing defects, and three possible missense changes. Each mutation was detected in just one family (although one has been described elsewhere); no mutation hot spot was identified. The nature and distribution of mutations, plus the lack of a clear phenotype/genotype correlation, suggest that they may inactivate the molecule. RT-PCR/PTT proved to be a rapid and efficient method to detect PKD1 mutations (differentiating pathogenic changes from polymorphisms), and we recommend this procedure as a firstpass mutation screen in this disorder.
常染色体显性多囊肾病主要基因(PKD1)的突变筛查一直很复杂,这是由于其转录本尺寸很大(>14 kb),且在同一染色体上编码75%蛋白质的基因组区域存在重复(HG位点)。PKD1和HG区域之间的序列相似性使得对PKD1重复区域进行特异性分析变得困难,因此所有先前描述的突变都定位在PKD1独特的3'区域。我们现在开发了一种新颖的锚定逆转录PCR(RT-PCR)方法,通过使用位于单拷贝区域内的一个引物和位于重复区域内的一个引物,特异性扩增PKD1的重复区域。该策略已被纳入对100名患者进行的突变筛查中,以检测超过一半的PKD1外显子(外显子22 - 46;占编码区域的37%),其中包括重复基因区域内的11个外显子(外显子22 - 32),采用蛋白质截短试验(PTT)。其中60名患者还通过非同位素核糖核酸酶切割试验(NIRCA)筛查了外显子23 - 36中的错义变化。已鉴定出11个突变,其中6个在重复区域内,包括3个终止突变、3个单核苷酸移码缺失、2个剪接缺陷和3个可能的错义变化。每个突变仅在一个家族中被检测到(尽管其中一个已在其他地方被描述);未发现突变热点。突变的性质和分布,加上缺乏明确的表型/基因型相关性,表明它们可能使该分子失活。RT-PCR/PTT被证明是检测PKD1突变(区分致病变化和多态性)的快速有效方法,我们推荐该方法作为这种疾病的初步突变筛查方法。